Stereotactic Radiosurgery (SRS) Induced Higher-Grade Transformation of a Benign Meningioma into Atypical Meningioma.
Journal
Case reports in surgery
ISSN: 2090-6900
Titre abrégé: Case Rep Surg
Pays: United States
ID NLM: 101580191
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
09
2021
revised:
09
10
2021
accepted:
19
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Stereotactic radiosurgery (SRS) is a widely used treatment modality for the management of meningioma. Whether used as a primary, adjuvant, or salvage procedure, SRS is a safe, less invasive, and effective modality of treatment as microsurgery. The transformation of a meningioma following radiosurgery raises a concern, and our current understanding about it is extremely limited. Only a few case reports have described meningioma dedifferentiation after SRS to a higher grade. Moreover, a relatively small number of cases have been reported in large retrospective studies with little elaboration. The risk of progression after SRS is low, and the risk of higher-grade transformation after SRS is trivial. The early timing for recurrence and field-related radiation may favor a relationship between SRS and higher-grade transformation (causality) although transformation as a part of the natural history of the disease cannot be fully excluded. Tumor progression (treatment failure) after SRS may demonstrate a transformation, and careful, close, and long follow-up is highly recommended. Also, acknowledging that there is a low risk of early and delayed complications and a trivial risk of transformation should not preclude its use as SRS affords a high level of safety and efficiency.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic radiosurgery (SRS) is a widely used treatment modality for the management of meningioma. Whether used as a primary, adjuvant, or salvage procedure, SRS is a safe, less invasive, and effective modality of treatment as microsurgery. The transformation of a meningioma following radiosurgery raises a concern, and our current understanding about it is extremely limited. Only a few case reports have described meningioma dedifferentiation after SRS to a higher grade. Moreover, a relatively small number of cases have been reported in large retrospective studies with little elaboration.
CONCLUSION
CONCLUSIONS
The risk of progression after SRS is low, and the risk of higher-grade transformation after SRS is trivial. The early timing for recurrence and field-related radiation may favor a relationship between SRS and higher-grade transformation (causality) although transformation as a part of the natural history of the disease cannot be fully excluded. Tumor progression (treatment failure) after SRS may demonstrate a transformation, and careful, close, and long follow-up is highly recommended. Also, acknowledging that there is a low risk of early and delayed complications and a trivial risk of transformation should not preclude its use as SRS affords a high level of safety and efficiency.
Identifiants
pubmed: 35251732
doi: 10.1155/2022/4478561
pmc: PMC8890901
doi:
Types de publication
Case Reports
Langues
eng
Pagination
4478561Informations de copyright
Copyright © 2022 Ali Basalamah et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Stereotact Funct Neurosurg. 2017;95(4):209-215
pubmed: 28683438
Can J Neurol Sci. 2012 Nov;39(6):757-62
pubmed: 23230622
Minim Invasive Neurosurg. 2009 Oct;52(5-6):216-21
pubmed: 20077361
J Neurosurg. 2013 Aug;119(2):487-93
pubmed: 23706054
J Neurosurg. 2018 Nov 1;129(5):1249-1259
pubmed: 29303453
J Neurosurg. 2008 Nov;109(5):804-10
pubmed: 18976068
J Clin Neurosci. 2015 Jan;22(1):161-5
pubmed: 25439747
J Neurosurg. 2015 Feb;122(2):363-72
pubmed: 25479122
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1436-41
pubmed: 20971572
J Neurooncol. 2012 Mar;107(1):13-20
pubmed: 22006176
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):919-923
pubmed: 28333013
Crit Rev Oncol Hematol. 2017 May;113:122-134
pubmed: 28427502
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9
pubmed: 15590183
J Neurosurg. 2014 Mar;120(3):708-15
pubmed: 24329019
Brain Tumor Res Treat. 2015 Oct;3(2):103-7
pubmed: 26605265
J Neurosurg. 2015 Jan;122(1):4-23
pubmed: 25343186
J Neurosurg. 2007 Jan;106(1):30-5
pubmed: 17236485
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1414-8
pubmed: 22209154
J Neurooncol. 2014 Aug;119(1):169-76
pubmed: 24821284
Br J Neurosurg. 2009 Apr;23(2):206-8
pubmed: 19306181
Clin Neurol Neurosurg. 2016 Mar;142:1-7
pubmed: 26795493
J Neurooncol. 2015 Jan;121(1):129-34
pubmed: 25186087
Neurosurg Clin N Am. 2013 Oct;24(4):499-507
pubmed: 24093568
Neurosurgery. 2007 Jan;60(1):60-5; discussion 65-6
pubmed: 17228253
Am J Clin Oncol. 2016 Oct;39(5):453-7
pubmed: 24755664
Clin Neurol Neurosurg. 2017 Feb;153:93-101
pubmed: 28081463
Exp Mol Pathol. 2015 Oct;99(2):354-9
pubmed: 26302177
Otolaryngol Clin North Am. 2009 Aug;42(4):717-29
pubmed: 19751875
J Neurosurg. 2007 Aug;107(2):325-36
pubmed: 17695387
Neurol Med Chir (Tokyo). 2009 Jun;49(6):258-61
pubmed: 19556736
Acta Neurochir (Wien). 2009 Jan;151(1):1-8
pubmed: 19093071
J Neurosurg. 2011 May;114(5):1399-409
pubmed: 21214335
Neurosurg Focus. 2007;23(4):E6
pubmed: 17961043
J Neurosurg. 2015 Jun;122(6):1479-89
pubmed: 25859812
Neurosurgery. 2010 Aug;67(2):322-8; discussion 328-9
pubmed: 20644417
Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9
pubmed: 20305491
Neurosurgery. 2012 Jan;70(1):32-9; discussion 39
pubmed: 21765282
Neurosurg Focus. 2003 May 15;14(5):e4
pubmed: 15669815
Acta Neurochir (Wien). 2011 Jan;153(1):62-7; discussion 67
pubmed: 20953804
Neurochirurgie. 2002 Feb;48(1):53-6
pubmed: 11972153
J Neurosurg. 2018 Jul 1;:1-10
pubmed: 30028261
J Neurosurg. 2013 Sep;119(3):675-82
pubmed: 23808540
Minim Invasive Neurosurg. 2005 Dec;48(6):334-9
pubmed: 16432782